#USA #Karyopharm #XPOVIO #Newton #KPTI

Karyopharm Therapeutics: Inducement Grants Announcement

Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a prominent player in the pharmaceutical sector focusing on innovative cancer therapies, has recently disclosed its grant of 1,450 restricted stock units (RSUs) to two newly appointed employees. This strategic move, publicized on March 2, 2026, aligns with the company's 2022 Inducement Stock Incentive Plan, modified to entice top talents in line with Nasdaq Listing Rule 5635(c)(4).

Details of the RSU Grants

The grant date for these RSUs was set for February 28, 2026. According to the terms outlined, the awarded units will vest progressively over the course of three years, with one-third of the shares becoming vested on each anniversary of the grant date. This method not only incentivizes the newly hired employees but also encourages them to remain with Karyopharm, fostering a stable and committed workforce.

These RSUs serve as a compelling tool for Karyopharm to attract skilled professionals who are keen to contribute to the fight against cancer. The pharmaceutical industry, especially oncology, is characterized by rapid advancements and intense competition, making it essential for companies like Karyopharm to offer substantial incentives to secure talented individuals.

About Karyopharm Therapeutics

Founded with the mission of transforming cancer care, Karyopharm Therapeutics has emerged as a leader in developing oral therapies that target nuclear export dysregulation - a significant mechanism involved in tumor development. Their flagship product, XPOVIO® (selinexor), is the first in its class and has received regulatory approvals in both the U.S. and globally. Additionally, it is marketed under the name NEXPOVIO® in the UK and has garnered attention in various cancer indications.

Karyopharm recognizes the challenges faced by cancer patients and stands committed to providing innovative therapies that improve their quality of life. Their product pipeline continues to expand and includes treatments aimed at several types of cancers with high unmet medical needs, such as multiple myeloma, diffuse large B-cell lymphoma (DLBCL), and endometrial cancer. The company's vision is not just to make a profit but to significantly impact patient lives through their groundbreaking work in oncology.

Future Outlook

Looking ahead, Karyopharm’s commitment to increasing its workforce and extending its pipeline of innovative therapies underscores its ambition to lead in the oncology space. The recently announced inducement grants exemplify this dedication. By bringing new talent onboard—who share the company’s vision of changing the cancer treatment landscape—Karyopharm is positioning itself for sustained growth and success in a highly competitive market.

In conclusion, Karyopharm Therapeutics is taking valuable steps to ensure it attracts and retains the best talent in the field, enhancing its capability to innovate and deliver on its promise to patients worldwide. The company's proactive approach in granting RSUs as part of employee compensation strategy reflects its understanding of the importance of human capital in the pharmaceutical industry.

For more information about Karyopharm, its lead products, and ongoing initiatives, visit their official site at www.karyopharm.com and engage with them on LinkedIn and X at @Karyopharm.

Karyopharm Therapeutics Inc. continues to pave the way in new cancer treatments, demonstrating its unwavering commitment not only to innovation but also to building a robust and capable workforce.